Skip to main content
. 2024 Jun 15;16(6):2504–2519. doi: 10.4251/wjgo.v16.i6.2504

Table 6.

Comparison of training set and validation set features, n (%)

Characteristic
Training cohort, n = 84
Internal test cohort, n = 36
P value
HBV-DNA 0.749
> 2000 37 (44) 17 (47)
≤ 2000 47 (56) 19 (53)
HBV 0.001
Negative 67 (80) 18 (50)
Positive 17 (20) 18 (50)
Antiviral therapy 0.806
No 18 (21) 7 (19)
Yes 66 (79) 29 (81)
Child Pugh score 0.022
A 30 (36) 21 (58)
B 54 (64) 15 (42)
PVTT 0.780
No 42 (50) 19 (53)
Yes 42 (50) 17 (47)
BCLC stage 0.690
B 41 (49) 19 (53)
C 43 (51) 17 (47)
Metastasis 0.936
No 46 (55) 20 (56)
Yes 38 (45) 16 (44)
AFP 0.035
> 1210 48 (57) 13 (36)
≤ 1210 36 (43) 23 (64)
Sex 0.837
Female 31 (37) 14 (39)
Male 53 (63) 22 (61)
Age 0.968
< 60 44 (52) 19 (53)
≥ 60 40 (48) 17 (47)
BMI 0.333
Low 48 (57) 25 (69)
Normal 5 (6.0) 3 (8.3)
Obese 5 (6.0) 0 (0)
Overweight 26 (31) 8 (22)
ECOG 0.491
0-1 48 (57) 23 (64)
2 36 (43) 13 (36)
Post operative 0.569
No 49 (58) 23 (64)
Yes 35 (42) 13 (36)
ALT 0.262
> 40 35 (42) 19 (53)
≤ 40 49 (58) 17 (47)
Total bilirubin 0.049
> 34 62 (74) 20 (56)
≤ 34 22 (26) 16 (44)
Diabetes 0.066
No 59 (70) 31 (86)
Yes 25 (30) 5 (14)
Hypertensive 0.827
No 24 (29) 11 (31)
Yes 60 (71) 25 (69)
Cirrhosis 0.245
No 44 (52) 23 (64)
Yes 40 (48) 13 (36)
Smoking 0.365
No 56 (67) 27 (75)
Yes 28 (33) 9 (25)
Alcohol 0.228
No 51 (61) 26 (72)
Yes 33 (39) 10 (28)
Virus reactivation 0.512
No 83 (99) 35 (97)
Yes 1 (1) 1 (3)

Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; PVTT: Portal vein tumor thrombosis.